Lv4
676 积分 2025-03-24 加入
Delivering silence: advancements in developing siRNA therapeutics
1小时前
求助中
Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis
18天前
已完结
siRNAs targeting ANGPTL3 for mixed dyslipidemia
21天前
已完结
Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
21天前
已完结
Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
21天前
已完结
Messenger interference RNA therapies targeting apolipoprotein C-III and angiopoietin-like protein 3 for mixed hyperlipidemia: the future of plozasiran and zodasiran
21天前
已完结
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors
1个月前
已完结
Targeted Delivery of Oligonucleotide-Peptide Conjugates for Enhanced Kidney-Specific Therapy
1个月前
已完结
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
1个月前
已完结
Molecular Mechanisms of Innate Immune Sensing of Exogenous RNAs
1个月前
已完结
皖公网安备34019202002308
